Koning Corporation Launches AI Software for 3D Breast CT
The artificial intelligence (AI) software facilitates high-resolution three-dimensional computed tomography (CT) images of the breast.
Could three-dimensional (3D) computed tomography (CT) be a game changer for early detection of breast cancer?
Koning Corporation has announced the launch of adjunctive artificial intelligence (AI) software that can produce 3D CT breast images through seamless integration with the company’s existing breast CT devices.
In addition to the high-resolution 3D images, Koning said the AI software provides significant noise and artifact reductions.
The company said the technological advancements with the new proprietary AI software may facilitate earlier detection of breast cancer.
“We are proud to introduce this revolutionary AI-enhanced breast CT software. This update to our current platform is set to redefine the standards of image quality in breast CT imaging, empowering radiologists to detect even the smallest irregularities at the earliest stages,” noted Lutao Ning, the chief executive officer of Koning.
(Editor’s note: For related content, see “Positron Emission Tomography: De-Escalation of Breast Cancer Treatment: What Emerging Research Reveals” and “Ultravist Becomes First FDA-Approved Contrast Agent for Contrast-Enhanced Mammography.”)
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.
AI-Initiated Recalls After Screening Mammography Demonstrate Higher PPV for Breast Cancer
March 18th 2025While recalls initiated by one of two reviewing radiologists after screening mammography were nearly 10 percent higher than recalls initiated by an AI software, the AI-initiated recalls had an 85 percent higher positive predictive value for breast cancer, according to a new study.
